$PFE Headlines Visa,

New Post Public Reply Private Reply Replies (0) Message Board

Dec 8, 2014 at 10:35 PM

$PFE Headlines

Visa, Goldman Sachs powering Dow to 18,000
4:29 p.m. Dec. 5, 2014
- Tomi Kilgore

Will Santa come to Broad and Wall?
1:54 p.m. Dec. 1, 2014
- The Trading Deck

Dow buy signals push index higher
11:39 a.m. Nov. 24, 2014
- The Trading Deck

Are consumers getting gouged on health care?
9:35 a.m. Nov. 22, 2014
- Russ Britt

AstraZeneca advances in London; pound rises as inflation ticks up
11:59 a.m. Nov. 18, 2014
- Carla Mozee

Zoetis unveils $500 million buyback plan
7:52 a.m. Nov. 18, 2014
- Michael Calia

AstraZeneca forecasts revenue of $45 bln by 2023
2:42 a.m. Nov. 18, 2014
- MarketWatch.com

Updates, advisories and surprises
6:01 p.m. Nov. 17, 2014
- MarketWatch

Urban Outfitters slides after earnings miss expectations
4:43 p.m. Nov. 17, 2014
- Sue Chang

U.K. stocks rise on Draghi stimulus talk; AstraZeneca drops
12:04 p.m. Nov. 17, 2014
- Carla Mozee

Pfizer, Germany’s Merck strike deal to develop cancer tumor treatment
11:05 a.m. Nov. 17, 2014
- Natalia Drozdiak

Pfizer, Germany's Merck to develop tumor treatment
10:22 a.m. Nov. 17, 2014
- MarketWatch.com

Halliburton-Baker Hughes Deal: Antitrust Issues?
9:27 a.m. Nov. 17, 2014
- MarketWatch

Mon., Nov. 17: Pfizer Stock After Pre-Market Drop
9:24 a.m. Nov. 17, 2014
- MarketWatch

Ford may be a buy, but U.S. stocks look stretched vs. the rest of the world
9:11 a.m. Nov. 17, 2014
- Shawn Langlois

Pfizer's stock drops after profit outlook cut
8:04 a.m. Nov. 17, 2014
- Tomi Kilgore

Pfizer's stock falls 1.6% in premarket trade
7:49 a.m. Nov. 17, 2014
- Tomi Kilgore

Pfizer previous EPS guidance was $1.50-$1.59
3:22 a.m. Nov. 17, 2014
- Karen Friar

Pfizer cuts 2014 EPS guidance to $1.40 to $1.49
3:22 a.m. Nov. 17, 2014
- Karen Friar

Pfizer, Merck to jointly develop cancer treatment
3:20 a.m. Nov. 17, 2014
- Karen Friar

Generic EpiPen Could Give These 2 Stocks A Jolt Of Adrenaline

4:48 p.m. Today4:48 p.m. Dec. 8, 2014
- Seeking Alpha

Assessing The Magnitude Of Pfizer's Coming Dividend Increase

3:11 p.m. Today3:11 p.m. Dec. 8, 2014
- Seeking Alpha

Merck Acquiring Cubist, Focusing On Hospital Care

10:48 a.m. Today10:48 a.m. Dec. 8, 2014
- Investors Business Daily

Pfizer Reports Expansion of Rare Disease Research with Establishment of Gene Therapy Platform

7:07 a.m. Today7:07 a.m. Dec. 8, 2014
- benzinga.com

Perky Dow Dividend Dogs Pop Up In December

4:14 a.m. Today4:14 a.m. Dec. 8, 2014
- Seeking Alpha

Health and Tech Funds Step Up

11:06 p.m. Dec. 7, 2014
- The Wall Street Journal Interactive Edition

What Eli Lilly Can Do To Keep Its Amazing Rally Going In 2015

5:07 p.m. Dec. 5, 2014
- Seeking Alpha

Will Someone Take GlaxoSmithKline Out Of Its Misery?

4:11 p.m. Dec. 5, 2014
- Seeking Alpha

The 4 Stocks That Carried the Market on Friday
3:30 p.m. Dec. 5, 2014
- 247WallSt.com

Bayer Doesn’t Look Ready for Animal Magnetism

8:22 a.m. Dec. 5, 2014
- The Wall Street Journal Interactive Edition

Can Albert Einstein's Math Get You To The Finish Line? Retirement Portfolio Quarterly Review

3:57 p.m. Dec. 4, 2014
- Seeking Alpha

Hot Drugmakers Build More Labs, Grab Space In Boston

3:47 p.m. Dec. 4, 2014
- Investors Business Daily

Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative
11:29 a.m. Dec. 4, 2014
- CNW Group

Dividend Dogs Of Healthcare: A 29.17% Advantage For The 5 Lowest Price High Yield Stocks

9:37 a.m. Dec. 4, 2014
- Seeking Alpha

5 Prime Dividend Dogs Of Healthcare Hound 11% To 45.4% November Upsides

3:40 a.m. Dec. 4, 2014
- Seeking Alpha

Puma Biotechnology Down on Delay in Neratinib NDA Filing - Analyst Blog

5:10 p.m. Dec. 3, 2014
- Zacks.com

Puma Biotech Stock Plunges On Drug Filing Delay

10:43 a.m. Dec. 3, 2014
- Investors Business Daily

Zoetis in a Growing Global Animal Health Industry

10:32 a.m. Dec. 3, 2014
- GuruFocus.com

2014’s Underperforming Large-Cap Stocks That Could Be 2015 Winners
7:37 a.m. Dec. 3, 2014
- 247WallSt.com

Pete Najarian Sees Unusual Options Activity In Pfizer

6:35 a.m. Dec. 3, 2014
- benzinga.com

Spark Therapeutics Announces Gene Therapy Collaboration in Hemophilia B with Pfizer Inc.
8:06 a.m. Today8:06 a.m. Dec. 8, 2014
- PR Newswire - PRF

Pfizer Expands Rare Disease Research with Establishment of Gene
Therapy Platform
8:02 a.m. Today8:02 a.m. Dec. 8, 2014
- BusinessWire - BZX

iTeos Therapeutics Announces License and Collaboration with Pfizer Inc. for Discovery and Development of Cancer Immunosuppression Targets
2:30 a.m. Today2:30 a.m. Dec. 8, 2014
- PR Newswire - PRF

Tenet Healthcare Names Dr. Freda C. Lewis-Hall to Board of Directors
4:00 p.m. Dec. 4, 2014
- BusinessWire - BZX

Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative
11:29 a.m. Dec. 4, 2014
- PR Newswire - PRF

Mylan receives tentative FDA approval for pediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative
10:00 a.m. Dec. 4, 2014
- PR Newswire - PRF

Phase 3 Results Published in TheNew England Journal of
Medicine Show Superiority of Pfizer’s XALKORI® (crizotinib)
Compared to Platinum-Based Chemotherapy in Previously Untreated Patients
With ALK-Positive Advanced Non-Small Cell Lung Cancer
5:07 p.m. Dec. 3, 2014
- BusinessWire - BZX

Diplomat selected as a limited-distribution pharmacy partner by Pfizer; Diplomat to dispense Xalkori®, Bosulif®, Sutent® and Inlyta®
4:37 p.m. Dec. 3, 2014
- PR Newswire - PRF

Lpath Completes Enrollment in its Phase 2 Clinical Trial of iSONEP for Wet Age-Related Macular Degeneration
4:05 p.m. Dec. 2, 2014
- PR Newswire - PRF

BioClinica Names Dr. John Hubbard Chief Executive Officer
9:14 a.m. Dec. 1, 2014
- PR Newswire - PRF

Pfizer Completes Acquisition of Baxter’s Marketed Vaccines
7:30 a.m. Dec. 1, 2014
- BusinessWire - BZX

TechNavio Names Pfizer, Merck, F. Hoffmann-La Roche as Top Companies in
the Global Human Growth Hormone Market
1:15 p.m. Nov. 20, 2014
- BusinessWire - BZX

Sanguine's Mobile Application to Assist Recruitment for Pfizer Inc. Chronic Pain Research
9:00 a.m. Nov. 18, 2014
- PR Newswire - PRF

TRUMENBA® (Meningococcal Group B Vaccine) is
Now Available
8:30 a.m. Nov. 18, 2014
- BusinessWire - BZX

Novel Agreement Expands Access to Pfizer’s Contraceptive, Sayana®
Press, for Women Most in Need in the World’s Poorest Countries
11:00 a.m. Nov. 13, 2014
- BusinessWire - BZX

Pfizer Highlights Leadership in Rheumatology and Inflammation with
Data to be Presented at the ACR/ARHP 2014 Annual Meeting
8:01 a.m. Nov. 12, 2014
- BusinessWire - BZX

Insider Trading Recap for AK Steel, Pfizer, Chesapeake Energy, Plug Power, Twitter, and RF Micro Devices
8:45 a.m. Nov. 11, 2014
- PR Newswire - PRF

Amy Schulman Joins The Board Of Directors Of Blue Buffalo
9:34 a.m. Nov. 10, 2014
- PR Newswire - PRF

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At
Healthcare Conference
11:00 a.m. Nov. 5, 2014
- BusinessWire - BZX

Pharma Stocks on our Radar - Pfizer, Merck, Sanofi, Shire, and Zogenix
8:55 a.m. Nov. 4, 2014
- PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...